U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07027670) titled 'Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery' on May 03, 2022.
Brief Summary: TALEN is a prospective randomised double-blind placebo-controlled phase 2 study of 5-Aminolevulinic Acid with Sodium Ferrous Citrate (5-ALA-SFC) in adult patients undergoing cardiac surgery on cardiopulmonary bypass (CPB). TALEN aims to identify the optimal biological dose (OBD) of 5-ALA-SFC.
Study Start Date: Feb. 01, 2021
Study Type: INTERVENTIONAL
Condition:
Cardiac Surgical Procedures
Coronary Artery Bypass
Aortic Valve Disease
Mitral Valve Disease
Intervention:
DRUG: 5-Aminolevulinic Acid hydrochloride (5-ALA) with Sodium Ferrous ...